Výsledky vyhledávání - "M Bustos Martinez"

PS-024 Pharmaceutical recommendations in traumatology department

Autor: I Ibarrondo Larramendi, O. Mora Atorrasagasti, A. López de Torre Querejazu, M Bustos Martinez, I. Palacios Zabalza, I Nuñez Ceruelo

Publikováno v: Patient safety and risk management.

Background Detection of drug related problems (DRP) and medication reconciliation (MR) are essential to decrease the harmful effects in patients. If any DRP is found during admission, it is important to notify not only the professional responsible bu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0607b0549af1c2a2b5e31fa6d79375b5
https://doi.org/10.1136/ejhpharm-2017-000640.530

Zobrazit plný text záznamu

OHP-005 Advantages and Disadvantages of an Electronic Prescribing System. Aspects to Consider During Pharmacist Validation

Autor: M.J. Martínez Bengoechea, B. Corcostegui Santiago, I Ibarrondo Larramendi, E Ibarra Garcia, E Ardanza Aramburu, M Bustos Martinez, I. Palacios Zabalza, O. Ibarra Barrueta, A. Santos Ibáñez

Publikováno v: European Journal of Hospital Pharmacy. 20:A137.2-A137

Background An electronic prescribing system (EPS) improves the prescription-validation-administration sequence and reduces errors. Nevertheless new questions can appear and it is interesting to take them into account. Purpose To describe positive and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::502e0e7ee53b680bad905ab4538a3f1c
https://doi.org/10.1136/ejhpharm-2013-000276.379

Zobrazit plný text záznamu

Local injection of infliximab for the treatment of perianal fistulas in Crohn¥s disease

Autor: M.J. Martínez-Bengoechea, A. Lopez-de-Torre Querejazu, J.L. Cabriada Nuño, I. Palacios Zabalza, A. de Juan Arroyo, E Ibarra Garcia, J. Peral Aguirregoitia, B. Corcostegui Santiago, M Bustos Martinez, O. Ibarra Barrueta

Publikováno v: European Journal of Hospital Pharmacy. 19:233.2-233

Background The formation of perianal fistulas is a serious complication that affects up to 30% of patients with Cohn9s disease (CD). It has been suggested that intrafistula injection of infliximab could have some potential healing benefit becoming an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ddc3b83d03b36f952bd165ccd623140d
https://doi.org/10.1136/ejhpharm-2012-000074.388

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání